Monitoring rFVIII prophylaxis dosing using global haemostasis assays

Haemophilia

Volumn 19, Issue 3, 2013, Pages 409-414

  Al Hawaj, M A ^a   Martin, E J ^a   Venitz, J ^a   Barrett, J C ^b   Kuhn, J G ^b   Nolte, M E ^b   Brophy, D F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Central Virginia Center for Coagulation Disorders   (United States)

Author keywords

Haemophilia A; rFVIII prophylaxis; TEG; Thrombin generation assay

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMPUTER PROGRAM; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURE; HEMOPHILIA A; HEMOSTASIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; THROMBIN GENERATION ASSAY; THROMBOELASTOGRAPHY;

ADULT; BLOOD COAGULATION TESTS; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; TIME FACTORS;

EID: 84876813697     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12110     Document Type: Article

References (32)

1. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
2. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
3. Björkman S. Prophylactic dosing of factor VIII and IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl 1.): 101-8.
4. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
5. Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2009; 8: 269-75.
6. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
7. Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-18.
8. Lee M, Morfinia M, Negrier C, Chamomaurd V. The pharmacokinetics of coagulation factors. Haemophilia 2006; 12(Suppl. 3): 1-7.
9. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
10. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
11. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
12. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413-20.
13. NHLBI Working Group: Can Global Assays Address Current and Future Challenges in Therapeutic Monitoring of Hemophilia A? Available at http://www.nhlbi.nih.gov/meetings/workshops/globalassays.htm. Accessed September 1, 2012.
14. Shima M, Matsumota T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 83-92.
15. Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global hemostasis and their application in bleeding disorders. Haemophilia 2010; 16(Suppl 5): 85-92.
16. Over J. Methodology of the one-stage assay for factor VIII (FVIII:C). Scand J Haematol 1984; 33(Suppl 41): 13-24.
17. Haemoscope™ (Internet). (place unknown); c1998-2007. Available at http://www.haemoscope.com. Accessed September 1, 2012.
18. Scarpelini S, Rhind SG, Nascimento B et al. Normal range values for thromboelastography in healthy adult volunteers. Braz J Med and Biol Res 2009; 42: 1210-17.
19. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-14.
20. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thromboelastography. Haemophilia 2005; 11(Suppl 1): 1-6.
21. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa - haemophilia and beyong. Semin Hematol 2004; 41: 140-4.
22. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: 348-52.
23. Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 96: 562-7.
24. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008; 19: 183-9.
25. van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res 2009; 123: 895-901.
26. Mann KG, Brummel-Ziedins K, Undas A, Butenas S. Does the genotype predict phenotype? Evaluations of hemostatic proteome. J Thromb Haemost 2004; 2: 1727-34.
27. Lewis SJ, Stephens E, Florou G et al. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. Br J Haematol 2007; 138: 775-82.
28. Santagostino E, Mancuso ME, Tripodi A et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.
29. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
30. Ay Y, Balkan C, Karapinar M, Akin M, Bilenoglu B, Kavakli K. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors. Haemophilia 2012; 18: 911-16.
31. Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-853.
32. Spronk HM, Dielis AW, Panova-Noeva M et al. Monitoring thrombin generation: is corn trypsin inhibitor needed? Thromb Haemost 2009; 101: 1156-62.